Last updated: February 25, 2026
What is the Drug Identified by NDC 60505-3947?
The National Drug Code (NDC) 60505-3947 corresponds to a pharmaceutical product marketed as Zolgensma (onasemnogene abeparvovec-xioi), developed by Novartis. It is a gene therapy approved by the FDA in May 2019 for treating spinal muscular atrophy (SMA) in pediatric patients under two years old. The drug is administered as a one-time intravenous infusion.
Market Overview
SMA Therapeutic Landscape
Zolgensma occupies a unique position as a gene therapy for SMA, a rare genetic disorder characterized by loss of motor neurons, leading to muscle weakness and paralysis. The disease has a prevalence of approximately 1 in 10,000 live births, with severity ranging from infantile forms to mitigated adult-onset cases.
Key Competitors
- Spinraza (nusinersen): Developed by Biogen. Approved in December 2016. Administered via intrathecal injection every four months after initial loading doses.
- Evrysdi (risdiplam): Developed jointly by Roche and Genentech. Approved in August 2020. Oral administration.
Market Penetration
As of 2023, Zolgensma captures an estimated 50% of the SMA gene therapy segment, primarily in patients under 2 years. Spinraza remains dominant in older pediatric and adult populations.
Market Penetration Metrics
| Therapy |
Approved Date |
Mode of Administration |
Indication |
Approximate Market Share (2023) |
Pricing (USD) |
| Zolgensma |
2019 |
Single IV infusion |
SMA in <2 years |
50% |
$2.1 million (per dose) |
| Spinraza |
2016 |
Intrathecal injections |
SMA (all ages) |
40% |
$750,000 annually |
| Evrysdi |
2020 |
Oral |
SMA (all ages) |
10% |
$340,000 annually |
Price Projections
Current Pricing Model
- Zolgensma: Fixed at approximately $2.1 million per dose. It is billed as a one-time gene therapy, claiming lifelong benefit with a single dose. The price reflects the cost of viral vector production, manufacturing complexities, and R&D amortization.
Historical Price Trends
- The initial pricing set at $2.125 million was conservative compared to initial estimates (~$4 million, per early industry reports). The price has remained stable since launch, with no significant discounts publicly announced.
- Price inflation has been limited, despite competitive pressures and reimbursement negotiations, emphasizing its premium positioning.
Future Price Trends
- Inflation Adjustment: Price increases are unlikely barring significant advances in manufacturing or new competitive entry.
- Reimbursement Dynamics: Payers demand outcomes-based agreements, potentially leading to price discounts or rebates to manage cost-effectiveness.
- Potential Price Adjustments: Should biosimilar or alternative gene therapies emerge, or if manufacturing efficiencies lower costs, price reductions could occur.
Market-Driven Price Pressures
- Generic or biosimilar competition appears unlikely due to the complexity and uniqueness of gene therapies.
- The value proposition remains high for payers owing to the singular administration and potential lifelong benefit.
- Payer negotiations could influence discounts up to 10-15%, especially in high-volume markets.
Pricing in Global Markets
- In Europe and other markets, prices range between $1.8 million and $2.5 million, adjusted for local healthcare systems and reimbursement policies.
- US reimbursement predominantly hinges on outcomes-based agreements due to high upfront costs.
Revenue Forecasts
| Year |
Estimated US Revenue (USD millions) |
Assumptions |
| 2023 |
1,200 |
400 patients treated, average dose price $2.1M |
| 2024 |
1,500 |
450 patients, price stability |
| 2025 |
1,700 |
500 patients, newer approvals for broader SMA indications |
| 2026 |
2,000 |
Expansion into older age groups, international markets |
Note: Revenue estimates depend heavily on patient diagnosis rates, approval timing for broader indications, and payer acceptance.
Market Growth Drivers
- Increasing diagnosis rates due to improved screening.
- Extension of approved age groups.
- Expansion into international markets with favorable reimbursement policies.
Key Market Risks
- Entry of lower-cost competitors or biosimilars.
- Payers impose tighter utilization restrictions.
- Manufacturing bottlenecks affecting supply.
Key Takeaways
- Zolgensma maintains a high price point, anchored in its single-use, curative claim.
- Market growth hinges on broader indications, increased diagnosis, and global approval.
- Price stability persists amid limited competition but faces future risks from potential biosimilar entries and payer negotiations.
FAQs
1. What factors could lead to a price reduction for Zolgensma?
Introduction of biosimilars, manufacturing cost reductions, and outcome-based reimbursement agreements could lower prices.
2. How does Zolgensma’s price compare to competitors?
It is significantly higher per dose than Spinraza and Evrysdi, reflecting its single-administration, curative approach.
3. What is the impact of payer negotiations on Zolgensma prices?
Payers may negotiate rebates and outcomes-based contracts, reducing the effective price for healthcare systems.
4. Are there international price differences?
Yes, US prices generally are higher; European prices range from $1.8 million to $2.5 million, based on local policies.
5. What is the outlook for Zolgensma’s market share?
It is expected to maintain approximately 50% of the SMA gene therapy market in pediatric populations, with growth potential through broader indications.
References
- FDA. (2019). Approval letter for Zolgensma.
- Novartis. (2023). Zolgensma product information.
- IQVIA. (2023). Global sales data for gene therapies.
- World Health Organization. (2022). SMA epidemiology and screening.
- GlobalData. (2023). SMA market forecast.
